KIDS

OrthoPediatrics is a genuine growth story in a defensible niche: the self-described "only global medical device company focused exclusively" on pediatric orthopedics, addressing a stated $6.2B global TAM ($2.8B U.S.) with 87 surgical/bracing systems, 45+ O&P clinics and ~232 dedicated sales reps. The top line proves the demand — revenue has compounded from $98M (FY2021) to $236M (FY2025), up 15.4% last year, with gross profit up 16.2% and a rich 73.1% gross margin. On sales the stock isn't demanding at a 2.1x P/S and a $504M cap. Liquidity optics are fine too: current assets of $256M against $46.2M current liabilities (≈5.5x) and modest leverage (liabilities/equity 0.47x).

The problem is that scale is not converting to profit. Net income has gotten worse, not better, even as revenue grew — FY2025 net loss of -$39.6M vs -$37.8M in FY2024 and a small profit back in FY2022. Operating income deteriorated another 12.1% to -$39.2M (-16.6% margin) and ROE is -11.4% against a -$275M accumulated deficit. The MD&A explains the structural drag: the consignment model forces "an up-front investment in inventory of consigned implants and instruments before we can generate revenue," so the business is inherently working-capital hungry, and management flags that international mix carries "a higher cost of revenue," pressuring margins as it expands across 75+ countries.